1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Characteristics of SS^a
Characteristics Sulcal SAH (n = 33)
Overt SAH (with Intraprocedural Contrast Extravasation)(n = 10) (30.3%) Covert SAH (without Intraprocedural Contrast Extravasation)(n = 23) (69.7%)
Management 
 Coil embolization 7 (70.0) 
 Observation 3 (30.0) 
Imaging findings 
 SAH detected solely by serial CT 5 (50.0) 2 (8.7)
 SAH detected by GRE/FLAIR 5 (50.0) 21 (91.3)
Location of SAH 
 Only Sylvian fissure 0 (0) 14 (60.9)
 Sylvian fissure + 1 sulcus 0 (0) 9 (39.1)
 Sylvian fissure + ≥2 sulci 5 (50.0) 0 (0)
 Diffuse, bilateral 5 (50.0) 0 (0)
Clinical outcomes 
 Neurologic deterioration 4 (40.0) 1 (4.3)
 mRS at 90 days^{^b} 4 (4–5) 2 (1–5)
 mRS 0–2 at 90 days 3 (30.0) 12 (52.2)
Mortality at 90 days 1 (10.0) 3 (13.0)
a Data are presented as number (%) except where otherwise noted.
↵b Data are median, and numbers in parentheses are interquartile range.